Results 11 to 20 of about 8,597,475 (170)

Faricimab 6 mg Versus Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Protocol-Standardised In Silico Study [PDF]

Pharmaceuticals
Background: Faricimab 6 mg and aflibercept 8 mg permit extended treatment intervals in neovascular age-related macular degeneration (nAMD), but their pivotal programmes used different loading and maintenance schedules.
Georgios D. Panos
doaj   +3 more sources

Initial Experiences of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population [PDF]

Ophthalmology and Therapy
Introduction Recent advances in the development of antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD) include the approval of aflibercept 8 mg, which delivers four times the previously ...
Chui Ming Gemmy Cheung, Wataru Kikushima, Kelvin Y. C. Teo   +2 more
doaj   +3 more sources

Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD. [PDF]

Eye (Lond)
Abstract Background/Objectives Sustainability is a major concern with the use of intravitreal therapy for neovascular age-related macular degeneration (nAMD), as case numbers rise with the ageing population.
Bowley N, Thomas P, Sivaprasad S, Purbrick RMJ, Beardmore E, Gilbert R, Clarke A, Chase TJG.   +7 more
europepmc   +4 more sources

Early intraocular pressure kinetics after intravitreal aflibercept 8 mg (0.07 mL) versus aflibercept 2 mg (0.05 mL) in nonglaucomatous eyes: a prospective comparative study [PDF]

International Journal of Retina and Vitreous
Background Transient intraocular pressure (IOP) spikes after intravitreal injection (IVI) are expected. The higher-volume aflibercept 8 mg (0.07 mL) formulation has recently entered clinical use, yet its early IOP kinetics—particularly the immediate post-
Annika Licht, Astrid Schneider, V. Romanou, Alireza Mirshahi   +3 more
doaj   +3 more sources

AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD. [PDF]

Eye (Lond)
Abstract Purpose To evaluate early morphological changes following intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration (nAMD) using artificial intelligence (AI)-assisted optical coherence tomography (OCT) segmentation.
Veritti D, Sarao V, Martin AA, Bonini F, Lanzetta P.   +4 more
europepmc   +4 more sources

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. [PDF]

Acta Ophthalmol
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study ...
Abu Ishkheidem I, Inci E, Breimer M, Silfverswärd ST, Zetterberg M, Grönlund MA.   +5 more
europepmc   +4 more sources

One-Month Real-World Comparison of Aflibercept 8 mg Versus 2 mg in Treatment-Naïve and Previously Treated Eyes with Neovascular Age-Related Macular Degeneration

Biologics
Background/Objectives: The relative efficacy of 8 mg aflibercept compared to 2 mg in treating neovascular age-related macular degeneration (nAMD) has not been fully established. This study aims to compare the visual and anatomical outcomes of aflibercept
Takahiro Mizukami, Satoru Ueno, Soichiro Mishima, Yoshikazu Shimomura   +3 more
doaj   +2 more sources

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

Life
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, Franziska Eckardt, Anna Lorger, Viktoria Deiters, Johannes Schiefelbein, Julian Elias Klaas, Benedikt Schworm, Siegfried G. Priglinger, Jakob Siedlecki   +10 more
doaj   +2 more sources

Short-term efficacy of aflibercept 8 mg in refractory neovascular age-related macular degeneration: a retrospective case series from Taiwan [PDF]

BMC Ophthalmology
Purpose Aflibercept 8 mg is a newly developed option for neovascular age-related macular degeneration (nAMD) class. This study explores the short-term effectiveness of aflibercept 8 mg in patients with refractory nAMD.
Sheng-Chu Chi, De-Kuang Hwang, Shih-Jen Chen, Chang-Chi Weng, Yi Ming Huang, Yu-Bai Chou, Tai-Chi Lin   +6 more
doaj   +2 more sources

Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report

BMC Ophthalmology
Background To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Nozomu Hashiya, Ichiro Maruko, Yuri Miyaguchi, Ruka Maruko, Taiji Hasegawa, Tomohiro Iida   +5 more
doaj   +2 more sources